Dorzolamide HCl CAS NO:130693-82-2

Dorzolamide HCl CAS NO:130693-82-2

CAS NO: 130693-82-2
Molecular Formula: C10H17ClN2O4S3
Molecular Weight: 360.90
EINECS NO: 620-304-2
MDL NO: MFCD00884659
Chat Now

Product Details

Product Description

Product Name: Dorzolamide HCl CAS NO:130693-82-2

 

 

Synonyms:

 

(4S,6S)-4-(ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride;

4H-Thieno[2,3-b]thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, (4S,6S)-, hydrochloride (1:1);

Dorzolamide hydrochloride;

(4S,6S)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide hydrochloride (1:1);

(4S,6S)-4-(Ethylamino)-5,6-dihydro-6-methyl-4H-thieno(2,3-b)thiopyran-2-sulfonamide 7,7-dioxide, monohydrochloride;

(4S,6S)-4-(Ethylamino)-6-methyl-5,6-dihydro-4H-thieno[2,3-b]thiopyran-2-sulfonamid-7,7-dioxidhydrochlorid;

4H-thieno[2,3-b]thiopyran-2-sulfonamide,4-(ethylamino)-5,6-dihydro-6-methyl-,7,7-dioxide, (4S,6S)-, monohydrochloride;

 

 

Chemical & Physical Properties

Appearance : White to off-white powder

Assay :≥99.0%

Density:1.53 g/cm3

Boiling Point:575.8℃ at 760 mmHg

Melting Point: 265-267℃

Flash Point:302℃

Solubility: Soluble in water, slightly soluble in methanol, very slightly soluble in anhydrous ethanol.

 

 

Dorzolamide Hcl(L671152 Hcl; MK507 Hcl) is an anti-glaucoma agent, which is a carbonic anhydrase inhibitor.Target: carbonic anhydrase (CA)Dorzolamide hydrochloride is a carbonic anhydrase inhibitor. It is an anti-glaucoma agent, and acts by decreasing the production of aqueous humour. Glaucoma was induced in the right eye of adult Wistar rats by episcleral venous occlusion. One experimental group was administered dorzolamide hydrochloride 2%-timolol 0.5% combination eye drops, while the other experimental group was administered dorzolamide hydrochloride2% eye drops. Control groups had surgery without drug administration. Drug application was initiated either 2 weeks before surgery (Group A), from the day of surgery (Group B), 2 weeks after surgery (Group C), or 4 weeks after surgery (Group D). RGCs were labeled by intratectal Fluorogold injections and counted from flat-mount preparations, and IOP was measured using Tonopen. Both dorzolamide-timolol combination and dorzolamide hydrochloride, when applied topically, significantly reduced IOP and improved RGC densities in experimental eyes when compared to control eyes. Earlier initiation, as well as longer duration of drug application, resulted in higher RGC densities [2].Clinical indications: Glaucoma; Ocular hypertensionFDA Approved Date: 1995.

 

 

If you are interested in our products or have any questions, please feel free to contact us!

 

 

Products under patent are offered for R & D purpose only. However, the final responsibility lies exclusively with the buyer.

 

 

 


Hot Tags: dorzolamide hcl cas no:130693-82-2, manufacturers, suppliers, factory, buy, in stock, CAS 86-98-6, Macitentan, CAS 290815-26-8, 3a-hydroxy-6-ethyl-7-keto-5ß-cholan-24-oic acid, CAS 196597-26-9, 2,3,5-Tri-O-benzyl-D-ribonolactone

Inquiry

You Might Also Like